ATE510841T1 - Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase - Google Patents

Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase

Info

Publication number
ATE510841T1
ATE510841T1 AT08762345T AT08762345T ATE510841T1 AT E510841 T1 ATE510841 T1 AT E510841T1 AT 08762345 T AT08762345 T AT 08762345T AT 08762345 T AT08762345 T AT 08762345T AT E510841 T1 ATE510841 T1 AT E510841T1
Authority
AT
Austria
Prior art keywords
disorders
kinase
thiazoliopyrimidines
phosphatidylinositol
kinase inhibitors
Prior art date
Application number
AT08762345T
Other languages
English (en)
Inventor
Timothy Hancox
Neil Pegg
Mandy Beswick
Toby Blench
Elsa Dechaux
Janusz Kulagowski
Alan Nadin
Stephen Price
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0711344A external-priority patent/GB0711344D0/en
Priority claimed from GB0715677A external-priority patent/GB0715677D0/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE510841T1 publication Critical patent/ATE510841T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08762345T 2007-06-12 2008-06-12 Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase ATE510841T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0711344A GB0711344D0 (en) 2007-06-12 2007-06-12 Pharmaceutical compounds
GB0715677A GB0715677D0 (en) 2007-08-10 2007-08-10 Pharmaceutical compounds
PCT/GB2008/002014 WO2008152390A1 (en) 2007-06-12 2008-06-12 Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase

Publications (1)

Publication Number Publication Date
ATE510841T1 true ATE510841T1 (de) 2011-06-15

Family

ID=39731164

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08762345T ATE510841T1 (de) 2007-06-12 2008-06-12 Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase

Country Status (7)

Country Link
US (2) US7893060B2 (de)
EP (1) EP2158207B1 (de)
JP (1) JP5539190B2 (de)
CN (1) CN101679456B (de)
AT (1) ATE510841T1 (de)
CA (1) CA2692050A1 (de)
WO (1) WO2008152390A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2916668B2 (ja) 1994-10-24 1999-07-05 三菱電線工業株式会社 ケーブル貫通部の防火構造
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
ATE510841T1 (de) * 2007-06-12 2011-06-15 Hoffmann La Roche Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
CN101932587A (zh) 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法
JP5638955B2 (ja) * 2007-10-26 2014-12-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｉ３キナーゼ阻害剤として有用なプリン誘導体
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8163763B2 (en) 2008-07-31 2012-04-24 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
EP2923734B1 (de) 2009-03-13 2018-01-10 Katholieke Universiteit Leuven, K.U. Leuven R&D Purineanaloga und ihre verwendung als immunosuppressiva
WO2010125799A1 (ja) 2009-04-27 2010-11-04 塩野義製薬株式会社 Pi3k阻害活性を有するウレア誘導体
SG182247A1 (en) * 2009-05-27 2012-08-30 Hoffmann La Roche Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
MX2011012520A (es) * 2009-05-27 2011-12-12 Hoffmann La Roche Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
WO2011058027A2 (en) 2009-11-12 2011-05-19 F. Hoffmann-La Roche Ag N-9-substituted purine compounds, compositions and methods of use
ES2567168T3 (es) 2009-11-12 2016-04-20 F. Hoffmann-La Roche Ag Compuestos purina y pirazolopirimidina N7-sustituidos, composiciones y métodos de utilización
WO2011080568A2 (en) * 2009-12-28 2011-07-07 Development Center For Biotechnology Novel pyrimidine compounds as mtor and p13k inhibitors
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
MX2013000389A (es) * 2010-07-14 2013-03-08 Hoffmann La Roche Compuestos de purina selectivos para fosfatidilinositol 3-cinasa p110 delta, y metodods de uso.
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
EA026134B1 (ru) 2010-12-16 2017-03-31 Ф. Хоффманн-Ля Рош Аг Трициклические ингибиторы pi3k и способы их применения
GB201119401D0 (en) * 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
ES2661510T3 (es) 2011-12-15 2018-04-02 Novartis Ag Uso de inhibidores de la actividad o función de PI3K
CN104350144B (zh) 2012-05-23 2017-08-04 弗·哈夫曼-拉罗切有限公司 获得和使用内胚层和肝细胞的组合物和方法
NZ705040A (en) 2012-07-20 2017-07-28 Cleave Biosciences Inc Fused pyrimidines as inhibitors of p97 complex
EP3049086A4 (de) * 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak-inhibitor und verwendungen davon
GB201402431D0 (en) * 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
WO2015185531A1 (de) 2014-06-05 2015-12-10 Bayer Cropscience Aktiengesellschaft Bicyclische verbindungen als schädlingsbekämpfungsmittel
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
KR101919189B1 (ko) 2016-02-18 2018-11-15 경북대학교 산학협력단 다중치환 4H-티아졸로[4,5-e][1,4]다이아제핀-5,8-다이온 유도체 및 이의 용도
CN116262758B (zh) * 2021-12-15 2025-02-28 上海博悦生物科技有限公司 7-甲基噻唑并[5,4-d]嘧啶类化合物、制备方法及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
AT321295B (de) * 1971-11-11 1975-03-25 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen Thiazolo[5,4-d]-pyrimidin-Derivaten und ihren Salzen
SK6652000A3 (en) * 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
AU4157500A (en) * 1999-03-26 2000-10-16 Astrazeneca Ab Novel compounds
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2005097746A2 (en) * 2004-04-12 2005-10-20 Torrent Pharmaceuticals Ltd 2-propene-1-ones as hsp 70 inducers
GB0412467D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB0508471D0 (en) 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents
US7605154B2 (en) * 2005-08-08 2009-10-20 Janssen Pharmaceutica N.V. Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
PL2041139T3 (pl) * 2006-04-26 2012-05-31 Hoffmann La Roche Związki farmaceutyczne
KR20090021155A (ko) * 2006-04-26 2009-02-27 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제제로서의 피리미딘 유도체
AU2007243466B2 (en) * 2006-04-26 2012-01-19 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
KR101533461B1 (ko) * 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체
PE20081679A1 (es) * 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
CA2671845C (en) * 2006-12-07 2015-03-24 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
ATE510841T1 (de) * 2007-06-12 2011-06-15 Hoffmann La Roche Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase
WO2008152394A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Pharmaceutical compounds
CN101932587A (zh) * 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法

Also Published As

Publication number Publication date
CN101679456B (zh) 2012-09-05
JP5539190B2 (ja) 2014-07-02
US20110098270A1 (en) 2011-04-28
US8168633B2 (en) 2012-05-01
JP2010529182A (ja) 2010-08-26
CA2692050A1 (en) 2008-12-18
US7893060B2 (en) 2011-02-22
WO2008152390A1 (en) 2008-12-18
EP2158207A1 (de) 2010-03-03
CN101679456A (zh) 2010-03-24
US20100190769A1 (en) 2010-07-29
EP2158207B1 (de) 2011-05-25

Similar Documents

Publication Publication Date Title
DE602008004650D1 (de) Pyrimidinderivate als inhibitoren von phosphatidylinositol-3-kinase
MX2009010881A (es) Compuestos farmaceuticos.
MX2009010884A (es) 2-morfolin-4-il-pirimidinas como inhibidores de fosfatidilinositol-3-cinasa (pi3k).
GB0423653D0 (en) Pharmaceutical compounds
ATE549336T1 (de) Heteroarylverbindungen,zusammensetzungen daraus und ihre verwendung als proteinkinasehemmer
MX2008013578A (es) Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
WO2008036308A3 (en) Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
ATE543819T1 (de) Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
WO2009011850A3 (en) Novel therapeutic compounds
NO20070484L (no) Sammenspleisede pyrimidinderivater og sammensetninger derav som CXCR3 reseptormodulatorer, anvendbare ved forebygging og behandling av inflammatoriske og immunregulatoriske lidelser og sykdommer.
WO2007084391A3 (en) Thiazole compounds as protein kinase b ( pkb) inhibitors
TNSN08227A1 (en) [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.
NO20074274L (no) Tetrahydroindolon og tetrahydroindazolonderivater
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
NO20084845L (no) 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig
MX2008014500A (es) 2,4-diaminopirimidinas como inhibidores de quinasas de ciclo de celulas.
NO20062357L (no) Indolinderivater og anvendelse av dem ved behandling av sykdomstilstander som cancer
SE0301232D0 (sv) Novel use
BR112013000867A2 (pt) composto de purina seletivos para delta p110 de pi3k e métodos de uso.
ATE435223T1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
EA200900913A1 (ru) Производное триазола в качестве ингибитора hsp90
ECSP099046A (es) Derivados ciclopropil amina
ATE521609T1 (de) Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs
MX2010004876A (es) Derivados de diamido tiazol como inhibidores de la proteina cinasa.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties